Q/C Technologies, Inc. (LON:0A8D)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 12.12M +367.8% |
| Revenue (ttm) | n/a |
| Net Income | -8.60M |
| EPS | -19.80 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,547 |
| Average Volume | 17,248 |
| Open | 4.080 |
| Previous Close | 4.040 |
| Day's Range | 3.850 - 4.080 |
| 52-Week Range | 2.614 - 63.950 |
| Beta | 2.23 |
| RSI | 46.19 |
| Earnings Date | Apr 10, 2026 |
About Q/C Technologies
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various... [Read more]
News
From Senior Living to Social Media, Massive Funding Rounds Signal AI's Mainstream Breakthrough
The artificial intelligence revolution isn’t just knocking; it’s bursting through the doors, and venture capital is fueling its relentless charge. From senior care to AI-powered social media, from Lon...
Microsoft signs $6.2B deal with Nscale Global, Aker to rent AI infrastructure in Norway
OpenAI spearheads one of Europes biggest data centers with 100,000 Nvidia chips
OpenAI said it is launching a Stargate AI data center in Norway which will be designed and built by Nscale and Aker.
Nscale, Aker, and OpenAI to launch Stargate Norway with 230 MW data center
SLB Capturi aims to clean up Europe’s polluting industry
A new JV between Norway's Aker and SLB Solutions is aiming to reduce the amount of pollutants spawned by European heavy industry.
Aker outlines 5% dividend growth for Aker BP in 2025 amid strong cash flow and portfolio streamlining
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger
BALTIMORE--(BUSINESS WIRE)--Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger
Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression Trial
BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company commit...
Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory Board
BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company commit...
Akers Biosciences Announces Shareholder Meeting to Vote on Business Combination with MyMD Pharmaceuticals
BALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)--Akers Biosciences, Inc (Nasdaq: AKER), today announced that it has scheduled its general meeting of shareholders (the "Meeting”) to vote on the proposed b...
SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations
NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights...
Akers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers
Akers Biosciences Inc (NASDAQ: AKER) and its proposed merger partner MyMD Pharmaceuticals Inc have announced new data for MYMD-1 from the Eurofins Discovery Phenotypic Center of Excellence study. MYMD...
MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery
BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending...
Study Identifies Effects of Temperature Changes on SARS-CoV-2 Transmission
BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending...
Akers Biosciences Responds to Erroneous Earnings Call Press Release
NEW YORK--(BUSINESS WIRE)--Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a compa...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - AKER, INFO, SNSS, WORK, WDR
NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Akers Biosciences, Inc. (NASDAQ: AKER) concerning po...
AKERS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Akers Biosciences, Inc. - AKER
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Akers Bioscien...
Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent
BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”) was issued US Pat. No. 10,835,523 B2, titled “M...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Akers Biosciences, Inc. - AKER
NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York C...
REMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. The companies plan to ho...
RM LAW Announces Investigation of Akers Biosciences, Inc.
BERWYN, Pa., Nov. 17, 2020 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of Akers Biosciences, Inc. ("Akers" or the "Company") (NASDAQ: AKER) regarding ...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc.
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akers Biosciences, Inc. ("Akers" or t...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Akers Biosciences, Inc.
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Akers Biosciences, Inc. (NASDAQ: AKER) and its board of directors concerning the propose...
Akers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement
BALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (“MyMD”) and Akers Biosciences, Inc. (“Akers”) (NASDAQ: AKER) today jointly announced that they have entered into a definitive ...
Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results
Thorofare, New Jersey, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partne...